Aripiprazole Augmentation of Antidepressants in PTSD

Durham VA Medical Center

Status and phase: Completed; Phase 2

Conditions: PTSD

Treatments: Drug: Placebo; Drug: Aripiprazole

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT00489866

VA IRB#01163

Details and patient eligibility

About

The proposed investigation will determine the therapeutic potential of aripiprazole augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder (PTSD) symptoms, cognitive symptoms, psychotic symptoms, and depressive symptoms in veterans with PTSD.

Enrollment: 14 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Outpatient veterans with posttraumatic stress disorder (PTSD)
• Receiving treatment with an antidepressant at a stable dose for 4 weeks
• Male or female
• Ages 18-65 years old

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

14 participants in 2 patient groups, including a placebo group

Aripiprazole

Experimental group

Treatment:

Drug: Aripiprazole

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo